...
机译:肾移植成功后肾原性系统性纤维化患者的结局
Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN;
Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN;
Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN;
Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN;
Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN;
Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN;
Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN;
Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN;
Department of Surgery, Division of Transplantation Surgery, Mayo Clinic Rochester, Rochester, MN;
Department of Surgery, Division of Transplantation Surgery, Mayo Clinic Rochester, Rochester, MN;
Department of Surgery, Division of Transplantation Surgery, Mayo Clinic Rochester, Rochester, MN;
Department of Surgery, Division of Transplantation Surgery, Mayo Clinic Rochester, Rochester, MN;
Department of Radiology, Mayo Clinic Rochester, Rochester, MN;
Department of Dermatology, Mayo Clinic Rochester, Rochester, MN;
Dermatology; kidney transplantation; skin; thymoglobulin;
机译:成功肾移植后发生肾原性系统性纤维化的患者的预后。
机译:成功肾移植后肾肾上腺素纤维化患者的结果。
机译:成功肾移植后肾肾上腺素纤维化患者的结果。
机译:DSA患者患者的肾脏移植的结果
机译:肾移植结果的回顾性分析:死者和活体供者肾脏移植患者中抗胸腺细胞球蛋白与Alemtuzumab的诱导免疫抑制作用。
机译:系统性AL淀粉样变性患者首次心脏和肾脏联合移植的成功长期结果
机译:成功肾移植后肾肾上腺素纤维化患者的结果